The cost-effectiveness of biosimilar denosumab in postmenopausal osteoporosis: implications of baseline fracture risk and drug price
Authors' conclusion
With sufficient price reductions, biosimilar denosumab is a dominant strategy across varying levels of baseline fracture risk.
Study context
- Population
- Women with postmenopausal osteoporosis (PMO) in the United States (US), across four baseline fracture risk categoriesmodel cohort
- Exposure
- Biosimilar denosumab vs alendronate, risedronate, ibandronate, zoledronic acid and no intervention
- Outcome
- Cost-effectiveness of biosimilar denosumab across baseline fracture risks and pricing scenarios
Methodological detailsMarkov cohort model, validated Markov cohort model, stratified into four risk categories by T-score and prior vertebral fracture, pricing scenario analyses
- Markov cohort model
- Validated Markov cohort model
- Stratified into four risk categories by T-score and prior vertebral fracture
- Pricing scenario analyses
Main finding
As reported in the abstract
Price at which biosimilar denosumab was dominant (more effective and less costly), by risk category
Risk category 1
$120-$180
Risk category 2
$376-$451
Risk category 3
$376-$481
Risk category 4
$857-$1188
Observational data: associations, not effects.
Further findings
Dominance at a 75% price reduction ($376)
- Dominant vs all comparators for risk categories 2, 3 and 4
- $376
Original publication
The cost-effectiveness of biosimilar denosumab in postmenopausal osteoporosis: implications of baseline fracture risk and drug price. Osteoporos Int. Published 31 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →